Fundz

Cresilon reported raising $25 Million in an initial SEC Form D filing, from an offering of $25 Million

PRIVATEOct 18, 2022Late filing, first sale Dec 17, 2021$25M of $25M raised

Amount Raised

$25 Million

$25 Million sold, per SEC Form D (first sale Dec 17, 2021)

Round Type

Venture

BrooklynBiotechnology

Quick answer

Cresilon raised $25 Million in a funding round, dated December 17, 2021. Cresilon is based in Brooklyn, New York, United States.

How much did Cresilon raise?
Cresilon raised $25 Million in a funding round on December 17, 2021.
What does Cresilon do?
Cresilon, Inc. is a privately held medical device company headquartered in Brooklyn, New York, specializing in hemostatic technologies designed to improve wound care and elevate the standard of medical treatment.
Where is Cresilon based and how big is it?
Cresilon is based in Brooklyn, New York, United States. Fundz records about 88 employees.
Who are the decision-makers at Cresilon?
Fundz holds 3 contacts at Cresilon, including the Vice President, Technology (Research & Development and Manufacturing Technology). Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Cresilon that raised within 45 days of this round, from Fundz verified event records.

  • Ribbon Biolabs raised $19M (Series A) on January 31, 2022.
  • Pheast Therapeutics raised $75M on January 31, 2022.
  • Soricimed Biopharma Inc. raised $1.4M (Seed) on January 31, 2022.
  • Vivace Therapeutics raised $30M on January 31, 2022.
  • Kula Bio raised $50M on January 28, 2022.
  • Crossfire Medical Inc raised $3M (Seed) on January 27, 2022.

Who to call at Cresilon, and when

A new round usually means Cresilon is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cresilon raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cresilon, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cresilon. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cresilon

Location

86 34th St., Suite 6-3-D

Brooklyn, New York, United States

About

Cresilon, Inc. is a privately held medical device company headquartered in Brooklyn, New York, specializing in hemostatic technologies designed to improve wound care and elevate the standard of medical treatment.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cresilon raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsIrene D., Vice President, Technology (Research &… hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Cresilon's next move

See what Strategic adds

Cresilon raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.